Entrada Therapeutics (TRDA) Financials

$6.56 +0.25 (+3.96%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$6.52 -0.04 (-0.69%)

As of 05/22/2026 07:55 PM Eastern

Annual Income Statements for Entrada Therapeutics

This table shows Entrada Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-97	-6.69	66
Consolidated Net Income / (Loss)	-95	-6.69	66
Net Income / (Loss) Continuing Operations	-95	-6.69	66
Total Pre-Tax Income	-95	12	66
Total Operating Income	-97	-3.16	47
Total Gross Profit	0.00	129	211
Total Revenue	0.00	129	211
Operating Revenue	0.00	129	211
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	97	132	164
Selling, General & Admin Expense	31	32	38
Research & Development Expense	67	100	125
Total Other Income / (Expense), net	2.63	15	19
Other Income / (Expense), net	2.63	15	19
Income Tax Expense	0.00	19	0.86
Basic Earnings per Share	($3.02)	($0.20)	$1.76
Weighted Average Basic Shares Outstanding	31.29M	33.05M	37.31M
Diluted Earnings per Share	($3.02)	($0.20)	$1.68
Weighted Average Diluted Shares Outstanding	31.29M	33.05M	39.00M
Weighted Average Basic & Diluted Shares Outstanding	33.08M	33.60M	37.59M

This table shows Entrada Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-25	-27	-6.67	-26	36	-10	23	55	-14	1.21
Consolidated Net Income / (Loss)	-25	-25	-6.67	-26	35	-9.54	23	55	-14	1.13
Net Income / (Loss) Continuing Operations	-25	-25	-6.67	-26	35	-9.54	23	55	-14	1.13
Total Pre-Tax Income	-25	-25	-3.12	-12	18	9.20	25	58	-16	-0.74
Total Operating Income	-26	-26	-5.78	-16	14	4.91	21	53	-22	-5.87
Total Gross Profit	0.00	-	25	18	44	42	59	95	20	37
Total Revenue	0.00	-	25	18	44	42	59	95	20	37
Operating Revenue	0.00	-	25	18	44	42	59	95	20	37
Total Operating Expenses	26	26	31	34	30	37	38	41	41	43
Selling, General & Admin Expense	6.98	9.89	7.94	8.17	7.53	8.65	9.40	9.24	9.97	9.86
Research & Development Expense	19	16	23	26	22	28	29	32	31	33
Total Other Income / (Expense), net	0.80	0.95	2.66	4.22	4.05	4.29	4.21	4.37	5.77	5.13
Other Income / (Expense), net	0.80	0.95	2.66	-	4.05	-	4.21	4.37	5.77	5.13
Income Tax Expense	0.00	-	3.55	14	-17	19	1.83	2.76	-1.86	-1.87
Basic Earnings per Share	($0.80)	($0.79)	($0.21)	($0.78)	$1.07	($0.28)	$0.70	$1.61	($0.35)	($0.20)
Weighted Average Basic Shares Outstanding	31.30M	31.29M	32.37M	33.16M	33.28M	33.05M	33.50M	34.18M	40.63M	37.31M
Diluted Earnings per Share	($0.80)	($0.79)	($0.21)	($0.78)	$1.02	($0.23)	$0.68	$1.55	($0.35)	($0.20)
Weighted Average Diluted Shares Outstanding	31.30M	31.29M	32.37M	33.16M	34.78M	33.05M	34.79M	35.51M	40.63M	39.00M
Weighted Average Basic & Diluted Shares Outstanding	31.41M	33.08M	33.20M	33.27M	33.37M	33.60M	33.76M	37.20M	37.42M	37.59M

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-242	22	34
Net Cash From Operating Activities	-94	140	-42
Net Cash From Continuing Operating Activities	-94	140	-42
Net Income / (Loss) Continuing Operations	-95	-6.69	66
Consolidated Net Income / (Loss)	-95	-6.69	66
Depreciation Expense	1.90	2.84	3.77
Amortization Expense	0.15	-5.78	-10
Non-Cash Adjustments To Reconcile Net Income	18	13	18
Changes in Operating Assets and Liabilities, net	-19	136	-119
Net Cash From Investing Activities	-149	-138	-28
Net Cash From Continuing Investing Activities	-149	-138	-28
Purchase of Property, Plant & Equipment	-2.89	-5.61	-3.16
Purchase of Investments	-222	-407	-438
Sale and/or Maturity of Investments	76	274	413
Net Cash From Financing Activities	0.48	21	103
Net Cash From Continuing Financing Activities	0.48	21	103
Issuance of Common Equity	0.20	21	103
Cash Income Taxes Paid	0.00	15	4.62

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-38	-8.15	182	-148	-28	16	0.83	117	-107	23
Net Cash From Operating Activities	-27	-27	203	-35	-24	-4.01	-26	40	-24	-32
Net Cash From Continuing Operating Activities	-27	-27	203	-35	-24	-4.01	-26	40	-24	-32
Net Income / (Loss) Continuing Operations	-25	-25	-6.67	-26	35	-9.54	23	55	-14	1.13
Consolidated Net Income / (Loss)	-25	-25	-6.67	-26	35	-9.54	23	55	-14	1.13
Depreciation Expense	0.52	0.53	0.54	0.73	0.83	0.74	0.93	0.91	0.94	0.99
Amortization Expense	-0.03	-0.10	-0.24	-1.69	-1.85	-2.00	-2.04	-2.26	-3.21	-2.51
Non-Cash Adjustments To Reconcile Net Income	2.71	11	2.76	3.12	3.40	3.84	3.73	4.62	4.86	4.70
Changes in Operating Assets and Liabilities, net	-5.54	-14	207	-11	-62	2.95	-52	-18	-13	-36
Net Cash From Investing Activities	-10	19	-40	-113	-3.74	19	26	-24	-83	53
Net Cash From Continuing Investing Activities	-10	19	-40	-113	-3.74	19	26	-24	-83	53
Purchase of Property, Plant & Equipment	-0.81	-0.71	-1.67	-1.52	-1.45	-0.98	-0.84	-1.05	-0.64	-0.64
Purchase of Investments	-39	-	-102	-140	-77	-89	-97	-111	-166	-64
Sale and/or Maturity of Investments	30	20	63	28	75	109	124	87	83	118
Net Cash From Financing Activities	0.06	0.36	20	0.44	0.37	0.69	0.21	101	-0.01	1.40
Net Cash From Continuing Financing Activities	0.06	0.36	20	0.44	0.37	0.69	0.21	101	-0.01	1.40
Issuance of Common Equity	-	0.20	19	0.19	-	1.44	0.00	100	-0.39	3.09

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	252	469	526
Total Current Assets	210	370	440
Cash & Equivalents	45	68	101
Short-Term Investments	144	284	319
Prepaid Expenses	21	12	16
Other Current Assets	0.00	5.88	3.68
Plant, Property, & Equipment, net	7.68	11	11
Total Noncurrent Assets	35	88	75
Other Noncurrent Operating Assets	35	88	75
Total Liabilities & Shareholders' Equity	252	469	526
Total Liabilities	40	227	98
Total Current Liabilities	22	159	39
Short-Term Debt	8.41	-	7.56
Accounts Payable	5.99	3.28	4.26
Accrued Expenses	7.58	11	13
Current Deferred Revenue	0.00	132	14
Current Deferred & Payable Income Tax Liabilities	0.00	4.02	0.67
Total Noncurrent Liabilities	18	68	58
Noncurrent Deferred Revenue	0.00	7.72	6.51
Other Noncurrent Operating Liabilities	18	60	52
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	213	242	429
Total Preferred & Common Equity	213	242	429
Total Common Equity	213	242	429
Common Stock	403	437	558
Retained Earnings	-188	-195	-129
Accumulated Other Comprehensive Income / (Loss)	-2.06	0.20	-0.04

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	274	476	494	485	511	582	555
Total Current Assets	235	434	390	383	414	490	465
Cash & Equivalents	53	228	80	52	68	185	78
Short-Term Investments	162	184	297	302	259	284	371
Prepaid Expenses	19	16	9.66	24	9.24	12	13
Other Current Assets	-	6.30	3.74	5.03	78	7.67	2.60
Plant, Property, & Equipment, net	7.44	9.39	11	11	11	11	11
Total Noncurrent Assets	32	32	93	91	86	81	78
Other Noncurrent Operating Assets	32	32	93	91	86	81	78
Total Liabilities & Shareholders' Equity	274	476	494	485	511	582	555
Total Liabilities	41	246	287	238	241	152	132
Total Current Liabilities	22	148	126	165	174	86	71
Short-Term Debt	-	-	-	-	-	-	7.74
Accounts Payable	1.34	6.47	2.42	0.75	2.53	1.64	1.29
Accrued Expenses	12	12	7.11	9.60	8.79	11	13
Current Deferred Revenue	-	122	102	148	148	60	46
Current Deferred & Payable Income Tax Liabilities	-	-	7.36	-	5.86	4.11	2.25
Total Noncurrent Liabilities	20	98	161	73	68	66	62
Capital Lease Obligations	-	-	-	-	-	-	54
Noncurrent Deferred Revenue	0.00	89	96	11	9.41	10	7.96
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	233	230	207	247	269	430	422
Total Preferred & Common Equity	233	230	207	247	269	430	422
Total Common Equity	233	230	207	247	269	430	422
Common Stock	400	425	429	433	441	547	552
Retained Earnings	-164	-195	-221	-185	-171	-116	-130
Accumulated Other Comprehensive Income / (Loss)	-2.75	-0.64	-1.01	-0.50	-0.25	-0.33	0.97

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	63.38%
EBITDA Growth	-84.99%	109.85%	560.67%
EBIT Growth	-84.95%	112.74%	451.47%
NOPAT Growth	-90.21%	102.58%	2,546.62%
Net Income Growth	-84.95%	92.93%	1,081.69%
EPS Growth	62.99%	93.38%	940.00%
Operating Cash Flow Growth	-84.39%	249.07%	-129.73%
Free Cash Flow Firm Growth	-118.97%	254.97%	-155.32%
Invested Capital Growth	321.32%	-439.89%	114.82%
Revenue Q/Q Growth	0.00%	48.01%	-2.07%
EBITDA Q/Q Growth	-7.08%	126.13%	16.32%
EBIT Q/Q Growth	-6.99%	135.83%	15.06%
NOPAT Q/Q Growth	-7.90%	107.44%	11.68%
Net Income Q/Q Growth	-6.99%	69.29%	19.43%
EPS Q/Q Growth	-122.17%	73.68%	1.82%
Operating Cash Flow Q/Q Growth	-7.77%	19.99%	-197.58%
Free Cash Flow Firm Q/Q Growth	0.00%	42.17%	20.38%
Invested Capital Q/Q Growth	82.73%	-2.52%	-52.82%
Profitability Metrics	-	-	-
Gross Margin	0.00%	100.00%	100.00%
EBITDA Margin	0.00%	7.07%	28.58%
Operating Margin	0.00%	-2.45%	22.30%
EBIT Margin	0.00%	9.34%	31.54%
Profit (Net Income) Margin	0.00%	-5.18%	31.13%
Tax Burden Percent	100.00%	-55.45%	98.71%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	155.45%	1.29%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-37.01%	-2.94%	19.56%
Cash Return on Invested Capital (CROIC)	-464.48%	0.00%	-489.22%
Operating Return on Assets (OROA)	0.00%	3.34%	13.36%
Return on Assets (ROA)	0.00%	-1.85%	13.18%
Return on Common Equity (ROCE)	-37.01%	-2.94%	19.56%
Return on Equity Simple (ROE_SIMPLE)	-44.51%	-2.76%	15.31%
Net Operating Profit after Tax (NOPAT)	-68	1.75	46
NOPAT Margin	0.00%	1.36%	22.02%
Net Nonoperating Expense Percent (NNEP)	-11.26%	-3.17%	5.03%
Return On Investment Capital (ROIC_SIMPLE)	-	0.72%	10.64%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	25.03%	18.25%
R&D to Revenue	0.00%	77.42%	59.45%
Operating Expenses to Revenue	0.00%	102.45%	77.70%
Earnings before Interest and Taxes (EBIT)	-95	12	66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-93	9.12	60
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.00	2.08	1.51
Price to Tangible Book Value (P/TBV)	2.00	2.08	1.51
Price to Revenue (P/Rev)	0.00	3.90	3.07
Price to Earnings (P/E)	0.00	0.00	9.86
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	10.14%
Enterprise Value to Invested Capital (EV/IC)	7.58	0.00	14.44
Enterprise Value to Revenue (EV/Rev)	0.00	1.17	1.11
Enterprise Value to EBITDA (EV/EBITDA)	0.00	16.62	3.89
Enterprise Value to EBIT (EV/EBIT)	0.00	12.57	3.53
Enterprise Value to NOPAT (EV/NOPAT)	0.00	86.44	5.05
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	1.08	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	1.06	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.04	0.00	0.02
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.92	-1.17	-1.14
Leverage Ratio	1.09	1.59	1.48
Compound Leverage Factor	1.09	1.59	1.48
Debt to Total Capital	3.80%	0.00%	1.73%
Short-Term Debt to Total Capital	3.80%	0.00%	1.73%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	96.20%	100.00%	98.27%
Debt to EBITDA	-0.09	0.00	0.13
Net Debt to EBITDA	1.95	0.00	-6.85
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	-0.12	0.00	0.16
Net Debt to NOPAT	2.65	0.00	-8.89
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	5.06	1.65	5.36
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	9.55	2.33	11.15
Quick Ratio	8.59	2.22	10.64
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-93	144	-79
Operating Cash Flow to CapEx	-3,248.56%	2,490.26%	-1,315.93%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.36	0.42
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	13.67	19.06
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	32	-110	16
Invested Capital Turnover	0.00	-3.34	-4.52
Increase / (Decrease) in Invested Capital	25	-142	126
Enterprise Value (EV)	244	152	235
Market Capitalization	425	504	647
Book Value per Share	$6.77	$7.26	$11.46
Tangible Book Value per Share	$6.77	$7.26	$11.46
Total Capital	221	242	436
Total Debt	8.41	0.00	7.56
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-180	-352	-412
Capital Expenditures (CapEx)	2.89	5.61	3.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.60	-141	-12
Debt-free Net Working Capital (DFNWC)	196	211	408
Net Working Capital (NWC)	188	211	401
Net Nonoperating Expense (NNE)	27	8.44	-19
Net Nonoperating Obligations (NNO)	-180	-352	-412
Total Depreciation and Amortization (D&A)	2.05	-2.94	-6.25
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-109.29%	-5.64%
Debt-free Net Working Capital to Revenue	0.00%	163.53%	193.62%
Net Working Capital to Revenue	0.00%	163.53%	190.03%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.02)	($0.20)	$1.76
Adjusted Weighted Average Basic Shares Outstanding	31.29M	33.05M	37.31M
Adjusted Diluted Earnings per Share	($3.02)	($0.20)	$1.68
Adjusted Weighted Average Diluted Shares Outstanding	31.29M	33.05M	39.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.08M	33.60M	37.59M
Normalized Net Operating Profit after Tax (NOPAT)	-68	-2.21	46
Normalized NOPAT Margin	0.00%	-1.72%	22.02%
Pre Tax Income Margin	0.00%	9.34%	31.54%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	134.05%	421.16%	-55.25%	-10.63%
EBITDA Growth	-74.50%	-33.87%	86.66%	23.53%	169.14%	115.05%	959.31%	426.99%	-206.59%	-161.89%
EBIT Growth	-74.20%	-33.51%	85.59%	29.68%	171.86%	119.92%	910.98%	454.56%	-187.98%	-115.07%
NOPAT Growth	-80.56%	-38.56%	73.91%	30.88%	251.52%	71.57%	584.10%	545.89%	-155.11%	19.32%
Net Income Growth	-74.20%	-33.51%	69.20%	-11.86%	241.07%	61.25%	452.05%	312.25%	-139.57%	111.85%
EPS Growth	91.82%	-104.98%	69.57%	-5.41%	227.50%	70.89%	423.81%	298.72%	-134.31%	13.04%
Operating Cash Flow Growth	-95.25%	-32.92%	1,068.98%	-94.85%	10.88%	85.30%	-112.55%	213.51%	0.92%	-687.57%
Free Cash Flow Firm Growth	-158.80%	0.00%	760.33%	701.78%	559.75%	421.81%	-154.52%	-146.51%	-202.91%	-195.02%
Invested Capital Growth	547.40%	321.32%	-1,449.39%	-1,541.50%	-705.82%	-439.89%	68.11%	76.56%	132.19%	114.82%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-28.07%	140.70%	-4.31%	41.27%	60.17%	-79.33%	91.10%
EBITDA Q/Q Growth	-9.22%	1.81%	88.35%	-512.27%	198.75%	-78.63%	565.13%	132.98%	-132.19%	87.59%
EBIT Q/Q Growth	-8.45%	2.02%	87.32%	-421.90%	210.82%	-72.85%	416.35%	128.17%	-127.50%	95.35%
NOPAT Q/Q Growth	-9.98%	1.38%	77.40%	-181.99%	341.10%	-118.50%	484.80%	159.73%	-129.80%	72.91%
Net Income Q/Q Growth	-8.45%	2.02%	72.90%	-288.49%	236.77%	-126.91%	346.19%	134.21%	-125.50%	108.06%
EPS Q/Q Growth	-8.11%	1.25%	73.42%	-271.43%	230.77%	-122.55%	395.65%	127.94%	-122.58%	42.86%
Operating Cash Flow Q/Q Growth	-52.60%	0.65%	844.94%	-117.25%	30.20%	83.62%	-535.91%	256.09%	-160.92%	-30.24%
Free Cash Flow Firm Q/Q Growth	-16.91%	-28.49%	550.51%	-11.08%	-10.68%	-10.06%	-176.32%	24.14%	-97.63%	16.96%
Invested Capital Q/Q Growth	49.75%	82.73%	-664.44%	6.67%	37.06%	-2.52%	47.04%	31.40%	186.43%	-52.82%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	0.00%	-11.16%	-94.99%	38.97%	8.70%	40.97%	59.60%	-92.84%	-6.03%
Operating Margin	0.00%	0.00%	-22.88%	-89.70%	32.04%	11.72%	35.71%	56.42%	-110.67%	-15.69%
EBIT Margin	0.00%	0.00%	-12.36%	-89.70%	41.30%	11.72%	42.84%	61.03%	-81.21%	-1.98%
Profit (Net Income) Margin	0.00%	0.00%	-26.42%	-142.70%	81.08%	-22.81%	39.74%	58.11%	-71.70%	3.02%
Tax Burden Percent	100.00%	100.00%	213.70%	214.62%	196.32%	-103.77%	92.77%	95.23%	88.30%	-153.04%
Interest Burden Percent	100.00%	100.00%	100.00%	74.12%	100.00%	187.50%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	-96.32%	203.77%	7.23%	4.77%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-49.39%	-37.01%	-31.41%	-35.58%	-9.07%	-2.94%	9.41%	32.80%	16.43%	19.56%
Cash Return on Invested Capital (CROIC)	0.00%	-464.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-289.92%	-489.22%
Operating Return on Assets (OROA)	0.00%	0.00%	-0.79%	-9.86%	9.48%	4.19%	14.15%	27.16%	-33.62%	-0.84%
Return on Assets (ROA)	0.00%	0.00%	-1.68%	-15.69%	18.61%	-8.16%	13.12%	25.86%	-29.69%	1.28%
Return on Common Equity (ROCE)	-22.15%	-37.01%	-31.41%	-35.58%	-9.07%	-2.94%	9.41%	32.80%	16.43%	19.56%
Return on Equity Simple (ROE_SIMPLE)	-37.92%	0.00%	-34.68%	-39.81%	-8.83%	0.00%	8.72%	24.29%	13.01%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-18	-4.05	-11	28	-5.09	20	51	-15	-4.11
NOPAT Margin	0.00%	0.00%	-16.02%	-62.79%	62.90%	-12.16%	33.13%	53.72%	-77.47%	-10.98%
Net Nonoperating Expense Percent (NNEP)	-4.13%	-2.85%	-0.78%	-4.68%	2.79%	-1.67%	1.06%	0.98%	0.30%	1.37%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-2.10%	-	-	-	-0.94%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	31.43%	44.96%	17.22%	20.67%	15.90%	9.75%	50.95%	26.36%
R&D to Revenue	0.00%	0.00%	91.46%	144.74%	50.74%	67.60%	48.39%	33.83%	159.72%	89.33%
Operating Expenses to Revenue	0.00%	0.00%	122.88%	189.70%	67.96%	88.28%	64.29%	43.58%	210.67%	115.69%
Earnings before Interest and Taxes (EBIT)	-25	-25	-3.12	-16	18	4.91	25	58	-16	-0.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-25	-24	-2.82	-17	17	3.64	24	56	-18	-2.25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.12	2.00	2.09	2.43	0.00	2.08	1.77	1.12	1.41	1.51
Price to Tangible Book Value (P/TBV)	2.12	2.00	2.09	2.43	0.00	2.08	1.77	1.12	1.41	1.51
Price to Revenue (P/Rev)	0.00	0.00	18.99	11.57	0.00	3.90	2.92	2.01	2.76	3.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	18.50	4.51	10.50	9.86
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.41%	22.16%	9.52%	10.14%
Enterprise Value to Invested Capital (EV/IC)	15.80	7.58	0.00	0.00	0.00	0.00	0.00	0.00	6.00	14.44
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	2.69	2.90	0.00	1.17	0.91	0.05	0.96	1.11
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	16.62	4.11	0.13	3.99	3.89
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	12.57	3.67	0.12	3.57	3.53
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	86.44	10.81	0.13	4.97	5.05
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.52	1.11	0.00	1.08	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.49	0.97	0.00	1.06	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.15	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.00
Financial Leverage	-0.94	-0.92	-1.33	-1.34	-1.19	-1.17	-1.48	-1.33	-1.11	-1.14
Leverage Ratio	1.14	1.09	1.56	1.71	1.58	1.59	1.98	1.69	1.55	1.48
Compound Leverage Factor	1.14	1.09	1.56	1.26	1.58	2.97	1.98	1.69	1.55	1.48
Debt to Total Capital	0.00%	3.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	12.67%	1.73%
Short-Term Debt to Total Capital	0.00%	3.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.60%	1.73%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	11.07%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	96.20%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	87.33%	98.27%
Debt to EBITDA	0.00	-0.09	0.00	0.00	0.00	0.00	0.00	0.00	1.18	0.13
Net Debt to EBITDA	0.00	1.95	0.00	0.00	0.00	0.00	0.00	0.00	-7.49	-6.85
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.03	0.00
Debt to NOPAT	0.00	-0.12	0.00	0.00	0.00	0.00	0.00	0.00	1.48	0.16
Net Debt to NOPAT	0.00	2.65	0.00	0.00	0.00	0.00	0.00	0.00	-9.34	-8.89
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.29	0.00
Altman Z-Score	6.99	5.98	1.35	1.05	0.00	1.60	1.76	3.19	3.52	4.94
Noncontrolling Interest Sharing Ratio	55.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.89	9.55	2.94	3.10	2.32	2.33	2.38	5.70	6.59	11.15
Quick Ratio	10.00	8.59	2.79	2.99	2.14	2.22	1.88	5.47	6.36	10.64
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-33	-42	191	170	152	137	-104	-79	-156	-130
Operating Cash Flow to CapEx	-3,392.84%	-3,856.50%	12,194.18%	-2,305.58%	-1,691.44%	-411.17%	-3,045.23%	3,808.13%	-3,797.50%	-4,977.17%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.06	0.11	0.23	0.36	0.33	0.45	0.41	0.42
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	3.05	4.62	9.43	13.67	15.97	21.41	19.72	19.06
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	18	32	-182	-170	-107	-110	-58	-40	34	16
Invested Capital Turnover	0.00	0.00	-0.30	-0.55	-1.95	-3.34	-1.36	-2.28	-5.94	-4.52
Increase / (Decrease) in Invested Capital	15	25	-196	-182	-125	-142	124	130	141	126
Enterprise Value (EV)	279	244	68	126	0.00	152	149	11	206	235
Market Capitalization	494	425	480	503	0.00	504	476	481	594	647
Book Value per Share	$7.43	$6.77	$6.94	$6.23	$7.41	$7.26	$8.02	$12.74	$11.36	$11.46
Tangible Book Value per Share	$7.43	$6.77	$6.94	$6.23	$7.41	$7.26	$8.02	$12.74	$11.36	$11.46
Total Capital	233	221	230	207	247	242	269	430	484	436
Total Debt	0.00	8.41	0.00	0.00	0.00	0.00	0.00	0.00	61	7.56
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	54	0.00
Net Debt	-216	-180	-412	-377	-354	-352	-327	-470	-388	-412
Capital Expenditures (CapEx)	0.81	0.71	1.67	1.52	1.45	0.98	0.84	1.05	0.64	0.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.39	7.60	-125	-113	-136	-141	-87	-66	-47	-12
Debt-free Net Working Capital (DFNWC)	213	196	287	264	218	211	240	404	402	408
Net Working Capital (NWC)	213	188	287	264	218	211	240	404	395	401
Net Nonoperating Expense (NNE)	6.98	6.72	2.63	15	-7.95	4.45	-3.91	-4.16	-1.13	-5.24
Net Nonoperating Obligations (NNO)	-216	-180	-412	-377	-354	-352	-327	-470	-388	-412
Total Depreciation and Amortization (D&A)	0.48	0.42	0.30	-0.96	-1.02	-1.26	-1.10	-1.35	-2.28	-1.52
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-495.21%	-259.12%	-155.99%	-109.29%	-53.53%	-27.58%	-21.78%	-5.64%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	1,134.37%	608.46%	249.65%	163.53%	147.50%	168.64%	186.99%	193.62%
Net Working Capital to Revenue	0.00%	0.00%	1,134.37%	608.46%	249.65%	163.53%	147.50%	168.64%	183.40%	190.03%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.80)	($0.79)	($0.21)	($0.78)	$1.07	($0.28)	$0.70	$1.61	($0.35)	($0.20)
Adjusted Weighted Average Basic Shares Outstanding	31.30M	31.29M	32.37M	33.16M	33.28M	33.05M	33.50M	34.18M	40.63M	37.31M
Adjusted Diluted Earnings per Share	($0.80)	($0.79)	($0.21)	($0.78)	$1.02	($0.23)	$0.68	$1.55	($0.35)	($0.20)
Adjusted Weighted Average Diluted Shares Outstanding	31.30M	31.29M	32.37M	33.16M	34.78M	33.05M	34.79M	35.51M	40.63M	39.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	31.41M	33.08M	33.20M	33.27M	33.37M	33.60M	33.76M	37.20M	37.42M	37.59M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-18	-4.05	-11	9.81	3.43	20	51	-15	-4.11
Normalized NOPAT Margin	0.00%	0.00%	-16.02%	-62.79%	22.43%	8.20%	33.13%	53.72%	-77.47%	-10.98%
Pre Tax Income Margin	0.00%	0.00%	-12.36%	-66.49%	41.30%	21.98%	42.84%	61.03%	-81.21%	-1.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Positives

Q2 2024: Net income from continuing operations of $55,031,000 and diluted earnings per share of $1.55; weighted-average basic & diluted shares outstanding about 37,199,550.
Q1 2024: Net income from continuing operations of $23,496,000 and basic EPS about $0.70 (diluted $0.68); weighted-average basic & diluted shares around 33,497,072.
Q4 2024: Net income attributable to common shareholders of $1,214,000; basic and diluted EPS around −$0.20, reflecting per-share effects of share count and accounting adjustments.
Strong liquidity in 2024: as of Q2 2024 the company held about $185.3M in cash and $284.5M in short-term investments (roughly $469.7M total), providing substantial liquidity runway.

Neutral

Revenue has been volatile in 2024: Q1 $59.12M, Q2 $94.69M, Q3 $19.57M, Q4 $37.40M, with no clear sustained growth trend.
Operating cash flow has been uneven: Q2 2024 generated about $39.83M, while Q1, Q3 and Q4 were negative (e.g., Q4 −$31.61M, Q3 −$24.27M, Q1 −$25.52M).
Shares outstanding show dilution over 2024 (weighted-average shares around 33.5M in Q1 2024 rising to about 37.2–37.6M in later quarters), which can pressure per-share metrics even when absolute profits occur.

Negatives

Ongoing cash burn: operating cash flow was negative in most quarters (e.g., Q4 2024 −$31.6M; Q3 2024 −$24.3M; Q1 2024 −$25.5M), indicating the company has struggled to generate consistent cash from operations.
Significant investing outflows in multiple quarters: e.g., Q2 2024 net cash from continuing investing activities −$24.38M and Q3 2024 −$82.93M, which reduce available cash and may reflect substantial investments or portfolio changes.
Earnings volatility: quarterly results show swings between profitability and losses (notably Q3 2024 net income from continuing operations negative at −$14.03M, with related EPS fluctuations), highlighting earnings variability.

05/24/26 10:02 AM ETAI Generated. May Contain Errors.

Entrada Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Entrada Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

Entrada Therapeutics' net income appears to be on a downward trend, with a most recent value of $65.63 million in 2024, falling from -$94.62 million in 2022. The previous period was -$6.69 million in 2023. Find out what analysts predict for Entrada Therapeutics in the coming months.

Entrada Therapeutics' total operating income in 2024 was $47.01 million, based on the following breakdown:

Total Gross Profit: $210.78 million
Total Operating Expenses: $163.77 million

Over the last 2 years, Entrada Therapeutics' total revenue changed from $0.00 in 2022 to $210.78 million in 2024, a change of 21,078,200,000.0%.

Entrada Therapeutics' total liabilities were at $97.64 million at the end of 2024, a 57.0% decrease from 2023, and a 147.2% increase since 2022.

In the past 2 years, Entrada Therapeutics' cash and equivalents has ranged from $45.16 million in 2022 to $101.21 million in 2024, and is currently $101.21 million as of their latest financial filing in 2024.

Over the last 2 years, Entrada Therapeutics' book value per share changed from 6.77 in 2022 to 11.46 in 2024, a change of 69.3%.

Related Companies

Financial statements for NASDAQ:TRDA last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entrada Therapeutics (TRDA) Financials

Financials Breakdown Chart

Key Financial Trends

Entrada Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entrada Therapeutics (TRDA) Financials

Annual Income Statements for Entrada Therapeutics

Quarterly Income Statements for Entrada Therapeutics

Annual Cash Flow Statements for Entrada Therapeutics

Quarterly Cash Flow Statements for Entrada Therapeutics

Annual Balance Sheets for Entrada Therapeutics

Quarterly Balance Sheets for Entrada Therapeutics

Annual Metrics And Ratios for Entrada Therapeutics

Quarterly Metrics And Ratios for Entrada Therapeutics

Financials Breakdown Chart

Key Financial Trends

Entrada Therapeutics Financials - Frequently Asked Questions

When does Entrada Therapeutics' fiscal year end?

How has Entrada Therapeutics' net income changed over the last 2 years?

What is Entrada Therapeutics' operating income?

How has Entrada Therapeutics' revenue changed over the last 2 years?

How much debt does Entrada Therapeutics have?

How much cash does Entrada Therapeutics have?

How has Entrada Therapeutics' book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools